Jazz Pharmaceuticals PLC $JAZZ Stock Position Reduced by William Blair Investment Management LLC

William Blair Investment Management LLC reduced its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 2.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 428,249 shares of the specialty pharmaceutical company’s stock after selling 8,644 shares during the period. William Blair Investment Management LLC owned about 0.67% of Jazz Pharmaceuticals worth $99,148,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. JW Asset Management LLC acquired a new position in Jazz Pharmaceuticals during the 3rd quarter worth about $2,547,000. Russell Investments Group Ltd. grew its position in Jazz Pharmaceuticals by 50.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 76,421 shares of the specialty pharmaceutical company’s stock valued at $17,696,000 after acquiring an additional 25,671 shares in the last quarter. Eurizon Capital SGR S.p.A. grew its position in Jazz Pharmaceuticals by 46.1% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $757,000 after acquiring an additional 1,029 shares in the last quarter. Maryland State Retirement & Pension System increased its stake in Jazz Pharmaceuticals by 19.0% during the third quarter. Maryland State Retirement & Pension System now owns 3,633 shares of the specialty pharmaceutical company’s stock worth $841,000 after purchasing an additional 580 shares during the period. Finally, Lido Advisors LLC increased its stake in Jazz Pharmaceuticals by 5.2% during the third quarter. Lido Advisors LLC now owns 2,644 shares of the specialty pharmaceutical company’s stock worth $612,000 after purchasing an additional 131 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Canaccord Genuity Group set a $300.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 26th. Piper Sandler lifted their price objective on shares of Jazz Pharmaceuticals from $310.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday. JPMorgan Chase & Co. upped their target price on shares of Jazz Pharmaceuticals from $300.00 to $310.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 3rd. Needham & Company LLC increased their target price on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Finally, Barclays raised their price target on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $294.25.

Check Out Our Latest Research Report on JAZZ

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $241.55 on Monday. The stock has a 50-day simple moving average of $229.13 and a 200-day simple moving average of $219.62. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.64 and a current ratio of 1.82. The stock has a market capitalization of $15.51 billion, a PE ratio of 82.16, a PEG ratio of 0.44 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 1 year low of $139.26 and a 1 year high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, topping analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the previous year, the company posted $8.13 earnings per share. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals PLC will post 11.08 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,413 shares of the firm’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $231.36, for a total value of $326,911.68. Following the sale, the chief accounting officer directly owned 6,512 shares in the company, valued at approximately $1,506,616.32. This trade represents a 17.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bruce C. Cozadd sold 68,808 shares of the firm’s stock in a transaction on Friday, November 6th. The shares were sold at an average price of $235.95, for a total transaction of $16,235,247.60. Following the completion of the sale, the director owned 357,567 shares in the company, valued at $84,367,933.65. The trade was a 16.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 171,342 shares of company stock worth $41,420,491 over the last ninety days. 4.10% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

(Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Further Reading

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.